A Phase 1B, Open Label Study Of Dalantercept Plus Sorafenib In Patients With Advanced Hepatocellular Carcinoma
Posted Date: May 15, 2019
- Investigator: Olugbenga Olowokure
- Type of Study: Drug
The purpose of this research study is to find out whether the study treatment can stop HCC from growing, or prevent it from growing as fast as it would without study treatment. This study will also evaluate the safety and tolerability of the study treatment in patients with HCC to determine the maxi
Criteria:
To Be Eligible For This Study, You Must Have Advanced Hepatocellular Carcinoma (Hcc) And You Require
Keywords:
Cancer, A041-05, Advanced Hepatocellu, Gi, Liver
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu